Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes

2017 ◽  
Vol 7 (4) ◽  
pp. 497-506 ◽  
Author(s):  
Jijin Gu ◽  
Karam Al-Bayati ◽  
Emmanuel A. Ho
NeuroImage ◽  
2019 ◽  
Vol 189 ◽  
pp. 267-275 ◽  
Author(s):  
Nick Todd ◽  
Yongzhi Zhang ◽  
Chanikarn Power ◽  
Lino Becerra ◽  
David Borsook ◽  
...  

2013 ◽  
Vol 39 (5) ◽  
pp. S26
Author(s):  
W. Feng ◽  
S. Yu ◽  
L. Lin ◽  
L. Li ◽  
C. Youli ◽  
...  

2007 ◽  
Vol 104 (18) ◽  
pp. 7594-7599 ◽  
Author(s):  
Brian J. Spencer ◽  
Inder M. Verma

Treatment of many neuronal degenerative disorders will require delivery of a therapeutic protein to neurons or glial cells across the whole CNS. The presence of the blood–brain barrier hampers the delivery of these proteins from the blood, thus necessitating a new method for delivery. Receptors on the blood–brain barrier bind ligands to facilitate their transport to the CNS; therefore, we hypothesized that by targeting these receptors, we may be able to deliver proteins to the CNS for therapy. Here, we report the use of the lentivirus vector system to deliver the lysosomal enzyme glucocerebrosidase and a secreted form of GFP to the neurons and astrocytes in the CNS. We fused the low-density lipoprotein receptor-binding domain of the apolipoprotein B to the targeted protein. This approach proved to be feasible for delivery of the protein and could possibly be used as a general method for delivery of therapeutic proteins to the CNS.


ChemMedChem ◽  
2018 ◽  
Vol 13 (13) ◽  
pp. 1311-1314 ◽  
Author(s):  
Tiffany G. Chan ◽  
Sophie V. Morse ◽  
Matthew J. Copping ◽  
James J. Choi ◽  
Ramon Vilar

Oncotarget ◽  
2017 ◽  
Vol 8 (39) ◽  
pp. 65339-65358 ◽  
Author(s):  
Arijit Bhowmik ◽  
Sayak Chakravarti ◽  
Aparajita Ghosh ◽  
Rajni Shaw ◽  
Suman Bhandary ◽  
...  

PLoS ONE ◽  
2012 ◽  
Vol 7 (12) ◽  
pp. e52925 ◽  
Author(s):  
Feng Wang ◽  
Yu Shi ◽  
Lin Lu ◽  
Li Liu ◽  
Youli Cai ◽  
...  

2012 ◽  
Vol 13 (4) ◽  
pp. 1067-1073 ◽  
Author(s):  
Chun-Fu Lien ◽  
Éva Molnár ◽  
Petr Toman ◽  
John Tsibouklis ◽  
Geoffrey J. Pilkington ◽  
...  

2020 ◽  
Vol 21 ◽  
Author(s):  
Mohammed Aslam ◽  
Md Noushad Javed ◽  
Hala Hasan Deeb ◽  
Michel Kaisar Nicola ◽  
Ayisha Md Sabir ◽  
...  

: Despite all significant research in discovering new therapeuticals, there has been an alarming rate of reported neurological disorders. However, the delivery of these neurotherapeuticals within the brain region is still a significant chal-lenge in the clinical management of neuronal disorders. Here, characteristic of the blood-brain barrier and blood-cerebrospinal fluid barrier serves the purpose of a physiological barrier to restrict the passage of systemic bioavailable neu-rotherapeuticals inside the brain, owing to low permeability and drug localization issues. The major advantage of such lipid-based delivery systems is that these are effective non–invasive techniques-based approaches that enable targeting of neuro-therapeuticals into the central nervous system. In the case of poorly water-soluble drugs, these lipid-based carriers not onlyfavor to increase bioavailability by enabling better solubility characteristics in the gastrointestinal tract but such encapsulat-ed neurotherapeuticals loads within the systems; may also favor stability. While owing to their small size and lipid-based composition, they offer enhanced permeability across the blood-brain barrier. These lipid-based nanocarriers effectively transport the encapsulated loads such as synthetic drugs, nutraceuticals, phytoconstituents, herbal extracts, or therapeuticalpeptides; across of these impermeable barriers to reduce the incidence of off-target mediated adverse impacts and toxicity. : In this review, we discussed, in brief, the potential of nanotechnology processed and lipid-based carriers, which are not onlyto enable higher penetration through the blood-brain barrier but also to maintain drug plasma levels in the desired range, ow-ing to control release profile. Apart from an increase in the extent of bioavailable fraction of drugs within the brain region, other attributes such as modulation in drug release, better penetration, the incidence of bypassing the first-pass metabolism to elevate half-lives; are further favoring the potential application of these carriers. Hence in this introductory review paper, a brief account of general introduction on limitation of neurotherapeuticals loaded conventional dosage forms, the blood-brain barriers as pharmacological barriers, challenges in brain targeted drug delivery, as well as potentials of different lipid-based nanoparticles and their patents, as emerging delivery solutions for neurotherapeuticals delivery; in the clinical man-agement of neuronal disorders; were thoroughly discussed.


Sign in / Sign up

Export Citation Format

Share Document